Skip to main
EXAS

Exact Sciences (EXAS) Stock Forecast & Price Target

Exact Sciences (EXAS) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Exact Sciences is positioned for significant growth, with its flagship Cologuard screening test expected to increase its market share from approximately 15% to over 40%, bolstered by strong demand and higher average selling prices. The company has demonstrated robust financial performance, achieving a 22% year-over-year growth in its core screening business, alongside recent improvements towards generating positive Adjusted EBITDA. With ambitious plans to scale screening efforts, targeting at least 30 million people by 2027, and a successful digital marketing campaign for its Cancerguard blood test, Exact Sciences is on track for continued revenue acceleration.

Bears say

Exact Sciences faces significant challenges that contribute to a negative outlook regarding its stock performance. The company's reliance on promotional marketing for Cologuard demand raises concerns about sustainability, especially given its historical pattern of net losses, casting doubt on its ability to achieve consistent GAAP profitability. Additionally, the projected revenue of $4.0 billion for 2027 falls short of targets, despite potential positive impacts from new agreements and product offerings, highlighting uncertainties within the company's financial growth trajectory.

Exact Sciences (EXAS) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exact Sciences (EXAS) Forecast

Analysts have given Exact Sciences (EXAS) a Buy based on their latest research and market trends.

According to 18 analysts, Exact Sciences (EXAS) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $86.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $86.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exact Sciences (EXAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.